cancer | American Cancer Society | breast cancer | National Cancer Institute | Cancer Research UK | Cancer | Memorial Sloan-Kettering Cancer Center | Fred Hutchinson Cancer Research Center | colorectal cancer | Tropic of Cancer | prostate cancer | Macmillan Cancer Support | Ludwig Institute for Cancer Research | liver cancer | Fox Chase Cancer Center | Colorectal cancer | Teenage Cancer Trust | Princess Margaret Cancer Centre | International Agency for Research on Cancer | Esophageal cancer | Breast Cancer Care | Breast Cancer | Union for International Cancer Control | Tropic of Cancer (novel) | Nevada Cancer Institute | Marie Curie Cancer Care | Juravinski Cancer Centre | Institute for Cancer Research | Eppley Institute for Research in Cancer and Allied Diseases | Clinical Cancer Research |
ALECSAT (Autologous Lymphoid Effector Cells Specific Against Tumor cells) technology is a novel method of epigenetic cancer immunotherapy being used by the company CytoVac.
Professor Dieli’s research has covered several aspects of human immunology: delayed-type hypersensitivity responses, immune response against Mycobacterium tuberculosis and cancer immunotherapy.